MedTrace Logo

Exploratory Study of Molecular Characterization in Patients With Metastatic Germ Cell Tumours Refractory/Resistant to Platinum Treatment

NCT03980587 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 18

Last updated 2019-06-10

No results posted yet for this study

Summary

1. To establish whether circulating tumour DNA is detectable in the plasma of patients with platinum refractory/resistant Germ Cell Tumours
2. If ctDNA is detectable, perform exploratory analyses to:

1. Describe the molecular aberrations in plasma from metastatic GCTs with platinum refractory/resistant disease
2. Describe aberrations detected in sequential detected in sequential samples form the same individual patient and evaluate whether there are hyposthesis-generating changes that temporarily associate with clinical resistance.

Conditions

  • Testicular Germ Cell Tumor

Sponsors & Collaborators

  • University College London (UCL) Cancer Institute

    collaborator OTHER

  • Royal Marsden NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Alison Reid · Royal Marsden NHS Foundation Trust

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-31
Primary Completion
2020-03-31
Completion
2021-08-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03980587 on ClinicalTrials.gov